Search results for " Sang"

showing 10 items of 268 documents

Invasive procedures and minor surgery in factor VII deficiency

2012

AdultMaleMINOR SURGERY INVASIVE PROCEDURES FACTOR VII DEFICIENCYAdolescentFactor VII DeficiencyBlood Loss SurgicalInfantHemorrhageHematologyFactor VIIHemostasiMiddle AgedSettore MED/15 - Malattie Del SangueMinor Surgical ProcedureYoung AdultCoagulantChild PreschoolSurgical Procedures OperativeFemaleChildGenetics (clinical)AgedHuman
researchProduct

Israeli Spotted Fever in Sicily. Description of two cases and minireview

2017

Mediterranean spotted fever (MSF) is endemic in Italy, where Rickettsia conorii subsp. conorii was thought to be the only pathogenic rickettsia and Rhipicephalus sanguineus the vector and main reservoir. R. conorii subsp. israelensis, which belongs to the R. conorii complex, is the agent of Israeli spotted fever (ISF); apart from Israel, it has also been found in Italy (Sicily and Sardinia) and in different regions of Portugal. We describe here two severe cases of ISF which occurred in otherwise healthy Italian adults. Their characteristics are analyzed and discussed in the light of other 91 cases found through a systematic review of international literature.

AdultMaleMicrobiology (medical)Settore MED/17 - Malattie InfettiveIsraeli spotted fever; Mediterranean spotted fever; Rickettsia israelensis; Microbiology (medical); Infectious DiseasesRhipicephalus sanguineus030231 tropical medicineBoutonneuse Feverlcsh:Infectious and parasitic diseases03 medical and health sciences0302 clinical medicinemedicineInternational literatureAnimalsHumanslcsh:RC109-216Rickettsia israelensi030212 general & internal medicineIsraelSicilyNormal rangebiologyMediterranean spotted feverGeneral Medicinebiology.organism_classificationmedicine.diseaseIsraeli spotted feverVirologySpotted feverBoutonneuse feverRickettsia conoriiInfectious DiseasesRickettsiaRickettsia israelensisVector (epidemiology)FemaleRickettsia conoriiInternational Journal of Infectious Diseases
researchProduct

Differential expression of specific microRNA and their targets in acute myeloid leukemia

2010

Acute myeloid leukemia (AML) the most common acute leukemia in adults is characterized by various cytogenetic and molecular abnormalities. However, the genetic etiology of the disease is not yet fully understood. MicroRNAs (miRNA) are small noncoding RNAs which regulate the expression of target mRNAs both at transcriptional and translational level. In recent years, miRNAs have been identified as a novel mechanism in gene regulation, which show variable expression during myeloid differentiation. We studied miRNA expression of leukemic blasts of 29 cases of newly diagnosed and genetically defined AML using quantitative reverse transcription polymerase chain reaction (RT-PCR) for 365 human miR…

AdultMaleNPM1Down-RegulationBiologySettore MED/15 - Malattie Del SangueYoung Adulthemic and lymphatic diseasesmicroRNAmedicineGene silencingHumansLeukemia microarray data microRNAGranulocyte Precursor CellsAgedCell ProliferationGeneticsRegulation of gene expressionAged 80 and overAcute leukemiaReverse Transcriptase Polymerase Chain ReactionGene Expression ProfilingCore Binding FactorsMyeloid leukemiaNuclear ProteinsCell DifferentiationHematologyMiddle Agedmedicine.diseaseUp-RegulationGene expression profilingGene Expression Regulation NeoplasticLeukemiaLeukemia Myeloid AcuteMicroRNAsfms-Like Tyrosine Kinase 3Case-Control StudiesMutationFemaleSettore SECS-S/01 - StatisticaNucleophosmin
researchProduct

Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in pati…

2012

Summary Von Willebrand disease (VWD) is an inherited bleeding disorder caused by the quantitative or qualitative deficiency of von Willebrand factor (VWF). Replacement therapy with plasma-derived VWF/factor VIII (FVIII) concentrates is required in patients unresponsive to desmopressin. To assess the efficacy, safety and ease of use of a new, volume-reduced (VR) formulation of VWF/FVIII concentrate Haemate® P in patients requiring treatment for bleeding or prophylaxis for recurrent bleeding or for invasive procedures. Pharmacoeconomic variables were also recorded. Data were analysed using descriptive statistics. This was a multicentre, prospective, observational study. Consecutively enrolled…

AdultMalePediatricsmedicine.medical_specialtyAdolescentBlood Loss SurgicalSevere diseaseHemorrhageSettore MED/15 - Malattie Del SangueYoung AdultVon Willebrand factorCost of Illnesshemic and lymphatic diseaseshemophiliavon Willebrand FactorVon Willebrand diseasemedicineHumansIn patientProspective StudiesDesmopressinAdverse effectChildGenetics (clinical)AgedFactor VIIIbiologybusiness.industryDrug SubstitutionAnticoagulantsHematologyGeneral MedicineMiddle Agedmedicine.diseaseResponse to treatmentHospitalizationvon Willebrand DiseasesItalyChild Preschoolbiology.proteinPasteurizationObservational studyFemalebusinessmedicine.drug
researchProduct

Incidence of venous thromboembolism in patients undergoing thoracotomy for lung cancer

2008

Limited information exists on the incidence of symptomatic venous thromboembolism (vTE) in patients undergoing chest surgery for lung cancer. Several factors increase the thromboembolic risk in patients undergoing surgery for lung cancer: the intrinsic procoagulant effect of cancer,extensive surgical intervention, dependent limb position in the operating room, and vessel injury consequent to the operation. Furthermore,these patients might be especially vulnerable to pulmonary embolism (PE) because of the loss of lung tissue and the presence of chronic obstructive pulmonary disease and cardiovascular diseases caused by smoking.t Older studies found a very high incidence of thromboembolic eve…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentSeverity of Illness Indexvenous thromboembolism thoracotomySettore MED/15 - Malattie Del SangueCohort StudiesAge DistributionPostoperative ComplicationsRisk FactorsmedicineHumansMulticenter Studies as TopicThoracotomySex DistributionLung cancerPneumonectomyAgedNeoplasm StagingRetrospective StudiesAged 80 and overOntariobusiness.industryVascular diseaseIncidence (epidemiology)IncidenceRespiratory diseaseCancerAnticoagulantsRetrospective cohort studyVenous ThromboembolismMiddle Agedmedicine.diseasePrognosisSurvival AnalysisSurgeryVenous thrombosisItalyThoracotomyFemaleSurgerybusinessPulmonary EmbolismCardiology and Cardiovascular MedicineThe Journal of Thoracic and Cardiovascular Surgery
researchProduct

Incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio.

2008

Objective Subtherapeutic international normalized ratios are frequently encountered in clinical practice, and patients with mechanical heart valves with inadequate anticoagulation may be exposed to an increased risk of thromboembolic events. There are no data on thromboembolic event risk for these patients. Methods We assessed the current practice patterns in the management of patients with mechanical heart valves with subtherapeutic international normalized ratios and assessed the risk of thromboembolic complications in this setting. The charts of patients with mechanical heart valves followed up in two anticoagulation clinics were reviewed. Patients with a history of stable, therapeutic a…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classLow molecular weight heparinProsthesis DesignRisk AssessmentSettore MED/15 - Malattie Del SangueCohort StudiesYoung AdultThromboembolismAntithromboticmedicineHumansInternational Normalized RatioINR anticoagulant mechanical heart valvesAgedRetrospective Studiesbusiness.industryIncidenceIncidence (epidemiology)Retrospective cohort studyMiddle AgedVitamin K antagonistConfidence intervalSurgeryHeart Valve ProsthesisFemaleSurgeryRisk assessmentbusinessCardiology and Cardiovascular MedicineCohort study
researchProduct

Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.

2011

We have previously identified sole +9, 13q- or 20q-, as 'favorable' and sole +8 or complex karyotype as 'unfavorable' cytogenetic abnormalities in primary myelofibrosis (PMF). In this study of 433 PMF patients, we describe additional sole abnormalities with favorable (chromosome 1 translocations/duplications) or unfavorable (-7/7q-) prognosis and also show that other sole or two abnormalities that do not include i(17q), -5/5q-, 12p-, inv(3) or 11q23 rearrangement are prognostically aligned with normal karyotype, which is prognostically favorable. These findings were incorporated into a refined two-tired cytogenetic-risk stratification: unfavorable and favorable karyotype. The respective 5-y…

AdultMaleRiskCancer Researchmedicine.medical_specialtyPathologyAdolescentChromosomal translocationmyelofibrosisGastroenterologycytogeneticsDisease-Free SurvivalSettore MED/15 - Malattie Del SangueInternal medicineComplex KaryotypemedicineHumansMyelofibrosisAgedAged 80 and overChromosome AberrationsLeukemiaHematologyPlatelet Countbusiness.industryHazard ratioKaryotypeHematologyMiddle AgedPrognosismedicine.diseaseConfidence intervalkaryotypeOncologyPrimary MyelofibrosisInternational Prognostic Scoring SystemKaryotypingOriginal ArticleFemalemyeloproliferativebusiness
researchProduct

Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists: a multi-centre, retrospective cohort study.

2009

summaryKnowledge on the natural history of mesenteric vein thrombosis (MVT) and of the efficacy and safety of long-term oral anticoagulant therapy (OAT) in this setting is based on small uncontrolled series of patients with a limited follow-up. It was the aim of the study to assess the natural history of MVT in a cohort of patients treated with OAT. The charts of all MVT patients currently attending or who have attended four anticoagulation clinics were reviewed. Information on risk factors, treatment, recurrence, major bleeding and mortality was collected. Seventyseven patients (mean age 49.2 years; 45 males) were included with a median follow-up of 36 months (range 2–204 months). Forty-si…

AdultMaleRiskmedicine.medical_specialtyVitamin Kmedicine.drug_classmedicine.medical_treatmentSettore MED/15 - Malattie Del SangueCohort StudiesRisk FactorsmedicineHumansVeinAgedRetrospective StudiesAged 80 and overVenous ThrombosisChemotherapybusiness.industryAnticoagulantAnticoagulantsRetrospective cohort studyHematologyMiddle Agedmedicine.diseaseSurgeryMesenteric ArteriesNatural historyVenous thrombosismedicine.anatomical_structuremesenteric vein thrombosisCohortFemalebusinessCohort study
researchProduct

Cancer patients requiring interruption of long-term warfarin because of surgery or chemotherapy induced thrombocytopenia: The use of fixed sub-therap…

2012

No data are available regarding the management of cancer patients requiring interruption of long-term vitamin-K antagonist (VKA) therapy. For this purpose, we tested the efficacy and safety of fixed doses of low-molecular weight heparin (LMWH) in substitution of VKA because of invasive procedures or chemotherapy-induced thrombocytopenia. In cancer patients on VKA, therapy was discontinued 5 ± 1 days before surgery or chemotherapy. Heparin was given at prophylactic dosage in patients at low risk and at fixed subtherapeutic doses (3,800 or 4,000 UI anti-FXa, b.i.d.) in those at high-risk for thrombosis. LMWH was reinitiated 12 hr after surgery and VKA the day after. In patients receiving chem…

AdultMaleRiskmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentLow molecular weight heparinAntineoplastic AgentsHemorrhagelow-molecular weight heparin (LMWH); long-term vitamin-K antagonist (VKA) therapy; cancer patientsSettore MED/15 - Malattie Del SanguePostoperative ComplicationsNeoplasmsThromboembolismAtrial FibrillationHumansThrombophiliaMedicinecancer thrombocytopenia low molecular weight heparinProspective StudiesProspective cohort studyAgedAged 80 and overChemotherapybusiness.industryIncidenceWarfarinAnticoagulantsCancerHematologyHeparinHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombocytopeniaThrombosisSurgeryClinical trialHeart Valve ProsthesisAnesthesialow-molecular weight heparin (LMWH)FemaleWarfarinlong-term vitamin-K antagonist (VKA) therapycancer patientsbusinessmedicine.drugAmerican Journal of Hematology
researchProduct

Methodological considerations to determine the effect of exercise on brain-derived neurotrophic factor levels.

2015

Objectives: Physical exercise up-regulates brain-derived neurotrophic factor (BDNF) in the brain and blood. However, there is yet no consensus about the adequate blood processing conditions to standardize its assessment. We aimed to find a reliable blood sample processing method to determine changes in BDNF due to exercise. Design and methods: Twelve healthy university students performed an incremental cycling test to exhaustion. At baseline, immediately after exercise, and 30 and 60 min of recovery, venous blood was drawn and processed under different conditions, i.e. whole blood, serum coagulated for 10 min and 24 h, total plasma, and platelet-free plasma. BDNF concentration was measured …

AdultMaleSerummedicine.medical_specialtyHemoconcentrationClinical BiochemistryPhysical exerciseHemoconcentraciónPlasmaEnzyme-linked immunosorbent assayNeurotrophic factorsInternal medicinePlasma sanguineoSurveys and QuestionnairesMedicineHumansPlateletEducación físicaExerciseWhole bloodBrain-derived neurotrophic factorBlood Specimen Collectionbusiness.industryBrain-Derived Neurotrophic FactorGeneral MedicineVenous bloodHemoconcentrationWhole bloodEndocrinologyHomogeneousbusinessEnergy MetabolismClinical biochemistry
researchProduct